» Articles » PMID: 37324094

Changes in Targeted Metabolomics in Lung Tissue of Chronic Obstructive Pulmonary Disease

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2023 Jun 16
PMID 37324094
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a common chronic lung disease and its incidence is steadily increasing. COPD patients and mouse models of COPD share some similarities in lung pathology and physiology. We performed this study to explore the potential metabolic pathways involved in the pathogenesis of COPD and to discover the COPD-associated biomarkers. Furthermore, we aimed to examine how much the mouse model of COPD was similar and different to human COPD in terms of the altered metabolites and pathways.

Methods: Twenty human lung tissue samples (ten COPD and ten controls) and twelve mice lung tissue samples (six COPD and six controls) were analyzed by targeted HM350 metabolomics, and multivariate and pathway analysis were performed by Kyoto Encyclopedia of Genes and Genomes (KEGG) database.

Results: The counts of many metabolites such as amino acids, carbohydrates and carnitines were changed in both COPD patients and mice compared to controls, respectively. While lipid metabolism was changed only in COPD mice. After KEGG analysis, we found these altered metabolites involved in COPD through aging, apoptosis, oxidative stress and inflammation pathways.

Conclusions: The expressions of metabolites changed in both COPD patients and cigarette smoke exposed (CS-exposed) mice. And there were also some differences between COPD patients and mouse models due to the differences between species. Our study suggested the dysregulation in amino acid metabolism, energy production pathway and perhaps lipid metabolism may be significantly related to the pathogenesis of COPD.

Citing Articles

Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology.

Roth-Walter F, Adcock I, Benito-Villalvilla C, Bianchini R, Bjermer L, Caramori G Allergy. 2023; 79(5):1089-1122.

PMID: 38108546 PMC: 11497319. DOI: 10.1111/all.15977.

References
1.
Conlon T, Bartel J, Ballweg K, Gunter S, Prehn C, Krumsiek J . Metabolomics screening identifies reduced L-carnitine to be associated with progressive emphysema. Clin Sci (Lond). 2015; 130(4):273-87. DOI: 10.1042/CS20150438. View

2.
Yoshida M, Minagawa S, Araya J, Sakamoto T, Hara H, Tsubouchi K . Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. Nat Commun. 2019; 10(1):3145. PMC: 6637122. DOI: 10.1038/s41467-019-10991-7. View

3.
Barupal D, Pinkerton K, Hood C, Kind T, Fiehn O . Environmental Tobacco Smoke Alters Metabolic Systems in Adult Rats. Chem Res Toxicol. 2016; 29(11):1818-1827. PMC: 6707370. DOI: 10.1021/acs.chemrestox.6b00187. View

4.
Zhou J, Li Q, Liu C, Pang R, Yin Y . Plasma Metabolomics and Lipidomics Reveal Perturbed Metabolites in Different Disease Stages of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020; 15:553-565. PMC: 7073598. DOI: 10.2147/COPD.S229505. View

5.
Ren X, Ma S, Wang J, Tian S, Fu X, Liu X . Comparative effects of dexamethasone and bergenin on chronic bronchitis and their anti-inflammatory mechanisms based on NMR metabolomics. Mol Biosyst. 2016; 12(6):1938-47. DOI: 10.1039/c6mb00041j. View